Skip to main content

Table 4 Characteristic totals for co-colonization at hospital admission

From: Risk factors for Candida colonization and Co-colonization with multi-drug resistant organisms at admission

Characteristic

N

Total (SDӨ,%)

With Co-col (SDӨ, %)

Without Co-col (SDӨ, %)

Age (avg., yr)

491

56.4 (15.1)

58.9 (17.4)

56.3 (15.0)

Body mass index (avg.)

486

28.6 (8.3)

28.9 (9.2)

28.6 (8.2)

Gender (male)

492

275 (55.9 %)

15 (5.8 %)

260 (94.5 %)

Gender (female)

492

217 (44.1 %)

18 (8.3 %)

199 (91.7 %)

Ambulatory Status (ambulatory)

492

353 (71.7 %)

21(5.9 %)

332 (94.1 %)

Alcohol use

492

154 (31.3 %)

12 (7.8 %)

142 (92.2 %)

Surgery

492

69 (14.0 %)

2 (2.9 %)

67 (97.1 %)

Coronary artery disease

492

109 (22.2 %)

8 (7.3 %)

101 (92.7 %)

Chemotherapy

492

62 (12.6 %)

3 (4.8 %)

59 (95.2 %)

Lung Disease

492

62 (12.6 %)

6 (9.7 %)

56 (90.3 %)

Hypertension

492

291 (59.1 %)

18 (6.2 %)

273 (93.8 %)

Immunosuppression

492

192 (39.0 %)

10 (5.2 %)

182 (94.8 %)

Malnutrition

491

77 (15.7 %)

14 (18.2 %)

63 (81.8 %)

Cancer

491

152 (31.0 %)

9 (5.9 %)

143 (94.1 %)

Peripheral vascular disease

492

35 (7.1 %)

3 (8.6 %)

32 (91.4 %)

Renal Failure

492

106 (21.2 %)

11 (10.4 %)

95 (89.6 %)

Steroids

492

172 (35.0 %)

9 (5.2 %)

163 (94.8 %)

Abdominal drain

491

21 (4.3 %)

1 (4.8 %)

20 (95.2 %)

Non-insulin dependent diabetes

492

50 (10.2 %)

4 (8.0 %)

46 (92.0 %)

Insulin-dependent diabetes

491

105 (21.4 %)

8 (7.6 %)

97 (92.4 %)

Foley Catheter

492

116 (24.2 %)

12 (10.3 %)

104 (89.7 %)

Hemodialysis

490

29 (5.9 %)

3 (10.3 %)

26 (89.7 %)

Neutropenia

490

14 (2.9 %)

1 (7.1 %)

13 (92.9 %)

Open wound

486

101 (20.8 %)

10 (9.9 %)

91 (90.1 %)

Surgical wound

490

76 (15.5 %)

6 (7.9 %)

70 (92.1 %)

Transplant

490

111 (22.7 %)

4 (3.6 %)

107 (96.4 %)

Vascular catheter

489

462 (94.5 %)

31 (6.7 %)

431 (93.3 %)

Vent support

492

19 (3.9 %)

2 (10.5 %)

17 (89.5 %)

History of Candida

492

56 (11.4 %)

5 (8.9 %)

51 (91.1 %)

History of MRSAӨ

492

28 (5.7 %)

8 (28.6 %)

20 (71.4 %)

History of VREӨ

492

8 (1.6 %)

1 (12.5 %)

7 (87.5 %)

History of GNӨ

492

41 (8.3 %)

4 (9.8 %)

37 (90.2 %)

Days in hospital in 2 years. prior to admit (avg., days)

489

34.1 (108.8)

34.1 (40.5)

34.1 (112.1)

Days in ICU in 2 years. prior to admit (avg., days)

492

1.5 (4.9)

4.5 (9.6)

1.3 (4.3)

Aminoglycosidesa

492

11 (2.2 %)

1 (9.1 %)

10 (90.9 %)

Carbapenemsa

492

4 (0.8 %)

2 (50.0 %)

2 (50.0 %)

1st Gen Cephalosporinsa

492

41 (8.3 %)

3 (7.3 %)

38 (92.7 %)

3rd Gen Cephalosporinsa

492

34 (6.9 %)

5 (14.7 %)

29 (85.3 %)

4th Gen Caphalosporinsa

492

12 (2.4 %)

1 (8.3 %)

11 (91.7 %)

Glycopeptides

492

32 (6.5 %)

5 (15.6 %)

27 (84.4 %)

Lincosamidesa

492

23 (4.7 %)

1 (4.3 %)

22 (95.7 %)

Macrolidesa

492

29 (5.9 %)

5 (17.2 %)

24 (82.8 %)

Penicillinsa

492

26 (5.3 %)

4 (15.4 %)

22 (84.6 %)

Penicillin Combinationsa

492

57 (11.6 %)

5 (8.8 %)

52 (91.2)

Fluoroquinolonesa

492

101 (20.5 %)

10 (9.9 %)

91 (90.1 %)

Sulfonamidesa

492

62 (12.6 %)

1 (1.6 %)

61 (98.4 %)

Drugs against mycobacteriaa

492

5 (1.0 %)

2 (40.0 %)

3 (60.0 %)

Other antibioticsb

492

21 (4.3 %)

5 (23.8 %)

16 (76.2 %)

  1. Ө SD standard deviation, MRSA Methicillin resistant Staphylococcus aureus, VRE Vancomycin resistant Enterococcus, RGN antibiotic resistant Gram-negative organisms
  2. All variables are dichotomous, yes vs. no, unless otherwise stated
  3. aAntibiotic use occurred prior to admission to hospital
  4. bOther antibiotics included use of either Metronidazole, Dapsone or Linezolid